Previous 10 |
home / stock / lobef / lobef news
Vancouver, British Columbia--(Newsfile Corp. - February 3, 2022) - Lobe Sciences Ltd. (the " Acquiror ") announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 3, 2022, it acquired 47,065,647 common shares in the capital of Ionic Brands Corp....
Vancouver, British Columbia--(Newsfile Corp. - January 7, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (" Lobe " or the " Company ") today announced that Philip Young, CEO and Director, will present at the H.C. Wainwright BIOCONNECT Conference taking place January 10-14, 2022. The pr...
"Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder" Vancouver, British Columbia--(Newsfile Corp. - December 21, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("...
Vancouver, British Columbia--(Newsfile Corp. - December 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (" Lobe " or the " Company ") is pleased to announce that it has received approval from OTC Markets Group Inc. ("OTCM") for its shares to trade on the OTCQB®. Lobe Scienc...
News, Short Squeeze, Breakout and More Instantly...
Company Exploring Alternative Value Creation Opportunities Convertible note for $500,000.00 USD, Short-term Debt Reduced and Balance Sheet Strengthened to Prepare the Company for Long Term Funding Strategy Annual General Meeting Set for 22 July 2024 Lobe Sciences Ltd. (O...
Accomplished Investor and Serial Entrepreneur Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced that Wesley Ramjeet has agreed to join its Board of Di...
Providing a Proven Track Record of Driving Growth and Innovation Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced that Frederick D. Sancilio Ph.D. ha...